•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Definium Therapeutics, Inc. (“Definium” or the “Company”) issued a statement supporting a newly signed White House Executive Order aimed at accelerating research, development, and responsible access to innovative treatments for serious mental illness, including emerging psychedelic medical treatments.
“Accelerating scientific progress depends on both rigor and urgency, and we thank the Administration and welcome this Executive Order as an important recognition of the persistent unmet treatment needs in serious mental illness,” said Rob Barrow, Chief Executive Officer of Definium Therapeutics. “We applaud the Administration’s recognition that psychedelic medicines may represent meaningful new treatment options for patients. We are advancing a comprehensive clinical development program for DT120 (lysergide tartrate) for millions of patients living with conditions including generalized anxiety disorder (GAD) and major depressive disorder (MDD). A science-driven framework that supports rigorous evaluation, responsible access, and faster translation of innovation into care is essential, and the FDA’s evidence-based approval process provides the most effective path to safely delivering these therapies to patients.”
The Executive Order directs coordinated federal action to prioritize mental health therapies, streamline regulatory pathways, and expand cross-agency collaboration. It is described as consistent with the Administration’s policy to accelerate innovative research models and appropriate drug approvals to increase access to psychedelic medicines that could help address the serious mental health crisis in America.
Definium said it remains committed to advancing rigorous clinical science to develop safe and effective psychedelic treatments and looks forward to continued collaboration with federal agencies, clinicians, researchers, and patient communities to advance evidence-based solutions for mental health disorders.
DT120 ODT (lysergide tartrate) is an ergoline derivative in the group of classic serotonergic psychedelics. It acts as a partial agonist at specific serotonin receptors, including human serotonin-2A (5-HT2A) receptors.
Definium described DT120 ODT as its proprietary and pharmaceutically optimized formulation of LSD. The company said the product incorporates Catalent’s Zydis® ODT fast-dissolve technology, designed to deliver advantages including faster absorption and onset of transient cognitive, perceptual, and affective changes, improved bioavailability, and a lower incidence of gastrointestinal side effects.
Definium is developing DT120 ODT, the tartrate salt form of lysergide, for generalized anxiety disorder (GAD) and major depressive disorder (MDD), and is exploring potential applications in other serious brain health disorders.
Definium Therapeutics’ mission is to develop a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments intended to address underlying causes of psychiatric and neurological disorders. The company is headquartered in New York and trades on Nasdaq under the symbol DFTX.
For more information, visit https://definiumtx.com/ and follow Definium Therapeutics on Instagram, LinkedIn and X.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
